Iloprost in Acute Respiratory Distress Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-25

Study Completion Date

2021-08-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The patients will be randomized into one of two groups. Both groups will receive standard care as is state of the art. The intervention group will receive Iloprost nebulized as inhalative therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Iloprost Effects on Gas Exchange and Pulmonary Mechanics

NCT01274481

Acute Respiratory Distress Syndrome Acute Lung Injury Pulmonary Hypertension

COMPLETED PHASE1

Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost

NCT00216931

Persistent Pulmonary Hypertension Respiratory Distress Syndrome

WITHDRAWN NA

Inhaled Iloprost for Suspected COVID-19 Respiratory Failure

NCT04445246

COVID-19 ARDS, Human Hypoxemic Respiratory Failure

COMPLETED PHASE2

Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure

NCT06319274

Acute Respiratory Failure Endothelial Dysfunction Pulmonary Infection

RECRUITING PHASE2

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

NCT04357730

Severe Acute Respiratory Syndrome Respiratory Failure Acute Respiratory Distress Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Distress Syndrome, Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Iloprost

Group Type ACTIVE_COMPARATOR

Iloprost

Intervention Type DRUG

Iloprost nebulized

control

Group Type PLACEBO_COMPARATOR

control

Intervention Type DRUG

sodium chloride 0,9% nebulized

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iloprost

Iloprost nebulized

Intervention Type DRUG

control

sodium chloride 0,9% nebulized

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Horowitz index \<300
* Bilateral opacities on frontal chest radiograph
* requirement of positive pressure ventilation
* no clinical evidence of left atrial hypertension
* enrollment within 48h of onset of ARDS
* mechanical ventilation \<7 days